Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

被引：0

作者：

Ashwell, Susan ^{[1
]}

Caleb, Benjamin L. ^{[1
]}

Deng, Chun ^{[1
]}

Green, Stephen ^{[2
]}

Grondine, Michael R. ^{[1
]}

Haye, Heather R. ^{[2
]}

Horn, Candice L. ^{[1
]}

Janetka, James W.

Liu, Dongfang ^{[1
]}

Mouchet, Elizabeth ^{[2
]}

Ready, Shannon ^{[1
]}

Rosenthal, Judith L. ^{[1
]}

Queva, Christophe ^{[1
]}

Taylor, Karen J. ^{[2
]}

Sheehy, Adam M. ^{[1
]}

Walker, Graeme E. ^{[2
]}

White, Anne M. ^{[2
]}

Zabludoff, Sonya D. ^{[1
]}

机构：

[1] AstraZeneca, Waltham, MA USA

[2] AstraZeneca, Macclesfield, Cheshire, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3411S / 3411S

页数：1

共 50 条

[21] Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
Liu, Yahong
Cheng, Ying
Huang, Gongchao
Xia, Xiangying
Wang, Xingkai
Tian, Hongqi
FRONTIERS IN PHARMACOLOGY, 2023, 14
[22] The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo
Ma, Zhikun
Ya, Guoliang
Zhou, Bo
Fan, Yonggang
Gao, Shegan
Feng, Xiaoshan
MOLECULAR MEDICINE REPORTS, 2012, 6 (04) : 897 - 903
[23] Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide
Erkin Ozgiray
Fatma Sogutlu
Cigir Biray Avci
Medical Oncology, 39
[24] Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma
Liu, Yan
Li, Yuyang
Wang, Xiaoen
Liu, Feiyang
Gao, Peng
Quinn, Max M.
Li, Fei
Merlino, Ashley A.
Benes, Cyril
Liu, Qingsong
Gray, Nathanael S.
Wong, Kwok-Kin
CANCER RESEARCH, 2017, 77 (18) : 5068 - 5076
[25] Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide
Ozgiray, Erkin
Sogutlu, Fatma
Avci, Cigir Biray
MEDICAL ONCOLOGY, 2022, 39 (11)
[26] Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
Leviten, Dina
Sierra, Teresa
Dozier, Ashley
Boyce, Richard
Boyle, Bob
Peterson, Scott
Vo, Alex C.
CANCER RESEARCH, 2017, 77
[27] Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization
Nilsson, Magnus
Berggren, Kristina
Berglund, Susanne
Cerboni, Silvia
Collins, Mia
Dahl, Goran
Elmqvist, David
Grimster, Neil P.
Hendrickx, Ramon
Johansson, Johan R.
Kettle, Jason G.
Lepisto, Matti
Rhedin, Magdalena
Smailagic, Amir
Su, Qibin
Wennberg, Tiiu
Wu, Allan
Osterlund, Torben
Naessens, Thomas
Mitra, Suman
JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 13400 - 13415
[28] Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin
Bingtao Liu
Weiqiang Chen
Hongbin Li
Feifei Li
Xiaodong Jin
Qiang Li
Radiation and Environmental Biophysics, 2020, 59 : 723 - 732
[29] Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3
Gayine, Paul R.
Mooney, Lorraine
Kilgour, Elaine
Thomas, Andrew P.
Al-Kadhimi, Katherine
Beck, Sarah
Coleman, Tanya
Baker, Dawn
Mellor, Martine J.
Brooks, Nigel A. N.
Klinowska, Teresa
CANCER RESEARCH, 2011, 71
[30] Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, Tim P.
Fennell, Mike
Whittaker, Robin
Curwen, Jon
Jacobs, Vivien
Allen, Jack
Logie, Armelle
Hargreaves, Judith
Hickinson, D. Mark
Wilkinson, Robert W.
Elvin, Paul
Boyer, Brigitte
Carragher, Neil
Ple, Patrick A.
Bermingham, Alun
Holdgate, Geoffrey A.
Warde, Walter H. J.
Hennequin, Laurent F.
Davies, Barry R.
Costello, Gerard F.
MOLECULAR ONCOLOGY, 2009, 3 (03) : 248 - 261

← 1 2 3 4 5 →